Active, Not Recruiting
A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept - IM101-645
Actualizada: 4 enero, 2022 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Géneros
Rango de edad
Active, Not Recruiting
Opciones de tratamiento
Inclusion Criteria: - Informed consent to participate in the study signed by the patient - Age ≥ 18 years at the date of consent subscription - Diagnosis of active Rheumatoid Arthritis moderate to severe as per the 1987 American College of Rheumatology (ACR) criteria/2010 ACR/ European League Against Rheumatism (EULAR) RA Classification Criteria - Naïve of abatacept - Initiated with abatacept SC either as 1st or 2nd line biologic treatment after inadequate response to previous therapy with one or more DMARDs according to Summary of Product Characteristics (SmPC) locally approved Exclusion Criteria: - Participating in clinical trial or other non-interventional studies, excluding registries - Inability to read and write - Any condition that in the investigator's opinion might jeopardize the follow-up and the data collection for the entire study observation period (24 months)
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
